P.62 INFLIXIMAB MODULATES MUCOSAL CYTOKINE PROFILE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Autor:	F. Bosè, Flavio Caprioli, Chiara Viganò, L. Raeli, D. Conte, Eva Reali, Sergio Abrignani, Guido Basilisco
Rok vydání:	2010
Předmět:	medicine.medical_specialty Hepatology Basic science business.industry Cytokine profile Gastroenterology Inflammatory Bowel Diseases medicine.disease Infliximab Liver disease Mrna level Internal medicine Genotype Medicine In patient business medicine.drug
Zdroj:	Digestive and Liver Disease. 42:S125
ISSN:	1590-8658
DOI:	10.1016/s1590-8658(10)60175-2
Popis:	s / Digestive and Liver Disease 42S (2010) S61–S192 S125 was significantly reduced compared to non-inflamed areas, both in CD and UC patients, (CD: Median = 0.34, Q1-Q3 = 0.17-0.74, p=0.001; UC: Median = 0.47, Q1-Q3 = 0.24-0.77, p=0.0004), irrespective of the risk genotypes for the rs2631367 variant. The differences remained still significant when comparing the normalized quantities (CD: p=0.0001; UC: p=0.000056). Conclusions: The OCTN2 and IL23R mRNA levels are significantly reduced in inflamed colonic mucosa, in both CD and UC patients, irrespective of patients’ genotypes. # G. Inflammatory bowel diseases 1. Basic science
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4d20e29b9c08f30dc86eada58f569a51 https://doi.org/10.1016/s1590-8658(10)60175-2 Zobrazit plný text záznamu Full Text from ScienceDirect